Editors' Note: After this story was published, FDA approved remdesivir to treat hospitalized COVID-19 patients 12 and over. A new World Health Organization-funded study that found remdesivir may not reduce mortality from COVID-19 could put pressure on its maker, Gilead, to cut the price of the antiviral, which is the only pandemic drug to receive an emergency use authorization. Remdesivir did not reduce the death rate or length of hospital stays among COVID-19 patients in the large...